Document is current
Any future updates will be listed below
-
Authors
Ito, Takanori https://orcid.org/0000-0002-1879-3550
Fukui, Sho https://orcid.org/0000-0002-3082-1374
Nagase, Fumika N. https://orcid.org/0000-0003-0737-282X
Yamaguchi, Toshihiro https://orcid.org/0009-0009-5659-0138
Oda, Nobuhiro https://orcid.org/0000-0003-3967-6414
Inokuchi, Hajime https://orcid.org/0009-0005-3514-3102
Suda, Masei https://orcid.org/0000-0002-2036-6216
Takizawa, Naoho https://orcid.org/0000-0003-3744-3537
Suyama, Yasuhiro https://orcid.org/0000-0002-9298-9121
Rokutanda, Ryo https://orcid.org/0000-0001-5966-6403
Nomura, Atsushi https://orcid.org/0000-0002-8194-6273
Uechi, Eishi https://orcid.org/0009-0006-6916-3491
Haji, Yoichiro https://orcid.org/0000-0001-5594-9123
Tamaki, Hiromichi https://orcid.org/0009-0009-9620-9995
- License Information
-
More Information
Article History
Received: 17 October 2024
Accepted: 29 January 2025
First Online: 10 February 2025
Declarations
:
: This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of St. Luke’s International Hospital (approval number: 20-R005, approval date: May 08, 2023).
: We obtained informed consent by offering options for opting out.
: No part of this manuscript, including the text and graphics, has been copied or published elsewhere, in whole or in part. The authors utilized an AI-based language model for minor language editing, including grammar and style checks. All intellectual content and scientific interpretations are the sole responsibility of the authors.
: TI received personal fees from Asahi Kasei Pharma, Sanofi, GSK, Eisai, Janssen Pharmaceutical, Boehringer Ingelheim, Taisho and Eli Lilly. NT received personal fees from AstraZeneca, Sanofi, Chugai Pharmaceutical, AbbVie, Tanabe-Mitsubishi, GSK, Pfizer, Eisai, Lilly, Taisho, and Novartis. YS received personal fees from Chugai Pharmaceutical. AN received personal fees from Asahi Kasei Pharma, Eisai, and Tanabe-Mitsubishi. HT received personal fees from AstraZeneca, Kissei Pharmaceutical, Asahi Kasei Pharma, Sanofi, Eisai, Chugai Pharmaceutical, AbbVie, Ono Pharmaceutical, Kyowa-Kirin, Takeda Pharmaceutical, Astellas Pharma, Tanabe-Mitsubishi, GSK, Pfizer, Dai-ichi-Sankyo, Lilly, and Ayumi. The other authors declare no conflicts of interest associated with this manuscript.
